Pharmaron Beijing Co (HKSE:03759) Construction In Progress: HK$2,622 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
93 GF Score
Price HK$23.66
GF Value HK$20.47
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Construction In Progress?

Pharmaron Beijing Co HKSE:03759 -0.17% 93 Construction In Progress is HK$2,622 Mil as of Mar. 2026. GuruFocus rates HKSE:03759 with a GF Score™ of 93/100 and a GF Value™ of HK$20.47 (Fairly Valued). The stock has 9 warning signs investors should review.

Pharmaron Beijing Co's quarterly construction in progress declined from Sep. 2025 (HK$2,679 Mil) to Dec. 2025 (HK$2,613 Mil) but then increased from Dec. 2025 (HK$2,613 Mil) to Mar. 2026 (HK$2,622 Mil).

Pharmaron Beijing Co's annual construction in progress declined from Dec. 2023 (HK$2,879 Mil) to Dec. 2024 (HK$2,406 Mil) but then increased from Dec. 2024 (HK$2,406 Mil) to Dec. 2025 (HK$2,613 Mil).

Pharmaron Beijing Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Construction In Progress Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,682.05 1,865.81 2,879.42 2,406.17 2,613.13

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,639.83 2,852.34 2,678.84 2,613.13 2,622.44
HKSE:03759
93GF Score
Pharmaron Beijing Co Ltd HKSE:03759
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$2,622 Mil mean?
Pharmaron Beijing Co (HKSE:03759) has a Construction In Progress of HK$2,622 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Construction In Progress too high?
Pharmaron Beijing Co's current Construction In Progress is HK$2,622 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Construction In Progress compare to VRTX and REGN?
Pharmaron Beijing Co's Construction In Progress of HK$2,622 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Construction In Progress is HK$2,622 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Fairly Valued. The stock's GF Value™ is HK$20.47, compared to a current price of HK$23.66 — trading 15.6% above its estimated fair value. The current Construction In Progress is HK$2,622 Mil. Pharmaron Beijing Co's overall GF Score™ is 93/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Construction In Progress is HK$2,622 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of HK$23.66 is trading 15.6% above its estimated GF Value™ of HK$20.47. GuruFocus considers Pharmaron Beijing Co to be Fairly Valued.

Key valuation signals for HKSE:03759:

  • Construction In Progress: HK$2,622 Mil
  • GF Value™: HK$20.47 vs. price of HK$23.66 (15.6% above fair value)
  • GF Score™: 93/100 with 9 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
93GF Score

Get the complete analysis for HKSE:03759

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$23.66
Price
HK$20.47
GF Value